Hmmm, 20 reasons for something, all from the past, without much looking at where things are today and where they may go, looking forward! I try to limit SWOT Analysis points to three or less per category.
S
- BIEL owns ActiPatch, an amazing, patented, FDA cleared, drug-free, side-effect free pain medical device that reduces pain and edema substantially and stimulates healing at the cellular level.
- Substantial OEM global players recognize potential markets of 2 billion plus users
- Numerous management changes and positive turnaround performance last 4Q
W
- Share price sub-penny for years due to lack of management skillset in the pharma/pain sector and predictable results
- Share structure remains heavily conflicted/biased as a result of previous management self-dealing. No longer with company, requires resolution
O
- OEM deals are real and progressing every day
- Current management is firing on all cylinders and there is a real opportunity that naysayers will continue to have diminishing effects on investor attitude
- Continuing low share price makes BIEL a Pink Sheet sleeper, providing management addresses the Whelan family shares structure issue
T
- Share structure inappropriately favors heirs of previous CEO
- Disgruntled stockholders
Every day is a day of great opportunity for BIEL! ActiPatch and RecoveryRx were never the issue blocking success. Current management is quickly reversing BIEL's past poor performance.
